Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | C.H. Boehringer Sohn AG and Co KG | 342 |
| 2 | Novartis AG | 93 |
| 3 | University of Pennsylvania | 71 |
| 4 | Chinese Center For Disease Control and Prevention | 69 |
| 5 | Bristol Myers Squibb Co | 56 |
| 6 | Cerus Corp | 56 |
| 7 | Pfizer Inc | 54 |
| 8 | Roche Holding AG | 49 |
| 9 | GSK PLC | 47 |
| 10 | Merck and Co Inc | 38 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 1,962 |
| 2 | A61P | Therapeutic activity (drug indications) | 1,922 |
| 3 | C07D | Heterocyclic compounds | 938 |
| 4 | Y02A | Climate change adaptation | 801 |
| 5 | C07K | Peptides | 552 |
| 6 | C12N | Microorganisms, enzymes | 455 |
| 7 | A01N | Preservation of bodies; biocides; pest repellents | 413 |
| 8 | G01N | Investigating / analysing materials | 161 |
| 9 | C07C | Acyclic and carbocyclic compounds | 156 |
| 10 | C12Q | Measuring/testing involving enzymes | 118 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Solubility parameter based drug delivery system and method for altering drug saturation concentration | 1997 | Hisamitsu Pharmaceutical Co Inc | 686 |
| Bioadhesive compositions and methods for topical administration of active agents | 2003 | Hisamitsu Pharmaceutical Co Inc | 505 |
| Biomarkers for theranostics | 2013 | Caris Life Sciences Inc | 240 |
| METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | 2017 | Wave Life Sciences Pte Ltd | 149 |
| Compositions and methods to effect the release profile in the transdermal administration of active agents | 2003 | Hisamitsu Pharmaceutical Co Inc | 368 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2024 | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Robert Bases | Albert Einstein College of Medicine | 12 |
| 2 | Erich Hirschberg | Columbia University | 10 |
| 3 | Sydney Archer | Sterling Research Group (United States) | 9 |
| 4 | J. Newsome | Medical Research Council | 8 |
| 5 | A. Halawani | 8 |
| 6 | Frances Mendez | Albert Einstein College of Medicine | 6 |
| 7 | Dennis B. Leeper | Thomas Jefferson University Hospital | 6 |
| 8 | I. Nabih | National Research Centre | 5 |
| 9 | J. Pellegrino | 5 | |
| 10 | Chantal Michel | University of Zurich | 4 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Lucanthone Is a Novel Inhibitor of Autophagy That Induces Cathepsin D-mediated Apoptosis | 2010 | 153 | Autophagy in Disease and Therapy |
| Hycanthone: A Frameshift Mutagen | 1971 | 148 | Antibiotic Resistance in Bacteria |
| Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone. | 2004 | 129 | DNA Repair Mechanisms |
| Graphene nanoribbons as a drug delivery agent for lucanthone mediated therapy of glioblastoma multiforme | 2014 | 114 | Graphene research and applications |
| A New, Active Metabolite of ‘Miracil D’ | 1965 | 106 | Microbial Natural Products and Biosynthesis |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Lucanthone Hydrochloride?
Which companies hold the most patents related to Lucanthone Hydrochloride?
What research topics are associated with published papers on Lucanthone Hydrochloride?
Who are the most prolific authors publishing on Lucanthone Hydrochloride?
What patent classification areas dominate the Lucanthone Hydrochloride patent landscape?